Treg cell depletion in adult mice results in activation of antigen-presenting cells prior to fatal autoimmune disease
نویسندگان
چکیده
Abstract Studies in mice expressing the diphtheria toxin receptor (DTR) exclusively on regulatory T (Treg) cells (Foxp3-DTR mice) demonstrated critical importance of Treg maintaining normal immune homeostasis. Adult Foxp3-DTR injected with DT begin to die from day 10 after treatment. Marked expansion almost all cell types was observed prior death. The purpose present studies examine in-depth changes lymphocytes and antigen-presenting at early time points depletion determine most controlled by steady state. Complete 2 days treatment, but profound activation CD4 +and CD8 +T as measured induction CD44 expression vigorous proliferation Ki-67 incorporation were not seen 6 Curiously, hiKi-67 CD25 −and plasma levels intracellular IL-2 increased suggesting that result a burst production. Increased CD80, CD86, CD40, PD-L1 could be detected CD11c +dendritic (DCs) 6. Anti-CD80/CD86 mAbs reversed provoked cells, while anti-IL-2 or anti-IL-2Rb had no effect. Taken together, these suggest disruption regulation Treg-mediated control DC represents first step complex autoimmune disease depletion. This work supported Intramural Research Program NIAID, NIH.
منابع مشابه
Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease.
We describe the generation of mice that express a transgenic T cell receptor (TCR) (5B6) specific for the encephalitogenic myelin proteolipid protein (PLP) peptide 139-151, on the experimental autoimmune encephalomyelitis-resistant (EAE-resistant) B10.S background. Despite harboring a high frequency of self-reactive T cells, 5B6 transgenic mice on the B10.S background rarely develop spontaneous...
متن کاملB cell depletion in autoimmune disease
The CD20 cell marker appears early in the process of B cell development. In this review we focus on the results of attempts to utilize B cell depletion based on the use of a chimeric monoclonal antibody (MAb) specific for human CD20, rituximab, for the treatment of patients with autoimmune diseases. In 1997, rituximab was approved for the treatment of low-grade B cell non-Hodgkin's lymphoma. Fo...
متن کاملTransient depletion of B cells in young mice results in activation of regulatory T cells that inhibit development of autoimmune disease in adults.
B-cell depletion therapy can be effective for treating B-cell lymphomas as well as many human and murine autoimmune diseases. B-cell-deficient mice are normally resistant to spontaneous autoimmune thyroiditis (SAT), but they develop SAT if regulatory T cells are transiently depleted during the first 3-6 weeks after birth. This was also a critical time when B-cell depletion effectively inhibited...
متن کاملB lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice.
Recent reports have shown that B cells play a key role in the pathogenesis of T cell-mediated autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM) in nonobese diabetic mice (NOD). We have investigated the role of B lymphocytes as APCs in the generation of autoreactive T cell responses by comparing spontaneous responses to self Ags in B cell-deficient and wild-type NOD mice. We...
متن کاملMechanisms by Which B Cells and Regulatory T Cells Influence Development of Murine Organ-Specific Autoimmune Diseases
Experiments with B cell-deficient (B-/-) mice indicate that a number of autoimmune diseases require B cells in addition to T cells for their development. Using B-/- Non-obese diabetic (NOD) and NOD.H-2h4 mice, we demonstrated that development of spontaneous autoimmune thyroiditis (SAT), Sjogren's syndrome and diabetes do not develop in B-/- mice, whereas all three diseases develop in B cell-pos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Immunology
سال: 2023
ISSN: ['1550-6606', '0022-1767']
DOI: https://doi.org/10.4049/jimmunol.210.supp.248.03